臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52798872 在线人数 : 646 教育部委托研究计画计画执行:国立台湾大学图书馆

搜寻范围

进阶搜寻

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"shih j y"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 401-410 / 1137 (共114页)
<< < 36 37 38 39 40 41 42 43 44 45 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-03-12T00:50:57Z	BMVC test, an improved fluorescence assay for detection of malignant pleural effusions	Lin I.-T.; Tsai Y.-L.; Kang C.-C.; Huang W.-C.; Wang C.-L.; Lin M.-Y.; Lou P.-J.; Shih J.-Y.; Wang H.-C.; Wu H.-D.; Tsai T.-H.; I-SHIOW JAN; Chang T.-C.
臺大學術典藏	2021-03-11T12:03:49Z	The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer	Yu K.-L.;Tsai T.-H.;Ho C.-C.;Liao W.-Y.;Ching-Kai Lin;Hsu C.-L.;Shih J.-Y.; Yu K.-L.; Tsai T.-H.; Ho C.-C.; Liao W.-Y.; CHING-KAI LIN; Hsu C.-L.; Shih J.-Y.
臺大學術典藏	2021-03-11T08:34:21Z	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma	Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih
臺大學術典藏	2021-03-11T08:34:19Z	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study	Liang S.-K.;Lee M.-R.;Liao W.-Y.;Ho C.-C.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; MENG-RUI LEE; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T08:34:18Z	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	Liang S.-K.;Jen-Chang Ko;Yang J.C.-H.;Shih J.-Y.; SHENG-KAI LIANG; JEN-CHANG KO; James Chih-Hsin Yang; Jin-Yuan Shih
臺大學術典藏	2021-03-11T08:34:15Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T08:34:15Z	Effect of β-Blocker in Treatment-Naive Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs	Chang C.-H.;Lee C.-H.;Jen-Chang Ko;Chang L.-Y.;Lee M.-C.;Zhang J.-F.;Wang J.-Y.;Shih J.-Y.;Yu C.-J.; CHIA-HAO CHANG; Lee C.-H.; JEN-CHANG KO; LIH-YU CHANG; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T08:29:35Z	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma	Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T08:29:34Z	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study	Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T08:29:32Z	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y.

显示项目 401-410 / 1137 (共114页)
<< < 36 37 38 39 40 41 42 43 44 45 > >>
每页显示[10|25|50]项目